J Clin Lab Anal . Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature

[tetano]

J Clin Lab Anal


. 2023 Apr 23;e24880.
doi: 10.1002/jcla.24880. Online ahead of print.
Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature


Da-Wei Yang ¹ , Min-Jie Ju ² , Hao Wang ³ , Yi-Chen Jia ⁴ , Xiao-Dan Wang ¹ , Hao Fang ^{5 6} , Jia Fan ⁷



Affiliations

• PMID: 37088868
• DOI: 10.1002/jcla.24880

Abstract

Background: The pandemic the coronavirus disease 2019 (COVID-19) has created a global health crisis. Although Paxlovid is recommended for the early-stage treatment of mild-to-moderate COVID-19 in patients at increased risk of progression to severe COVID-19, more and more cases are reported a COVID-19 rebound after Paxlovid treatment. Currently, information on the additional treatment for COVID-19 rebound following Paxlovid treatment is limited.
Case report: Here, we present four cases with COVID-19 who were mild on admission. All cases experienced a COVID-19 rebound and progressed to severe COVID-19, following treatment with Paxlovid (300 mg of nirmatrelvir with 100 mg ritonavir, twice daily for 5 days). After being treated with proxalutamide (300 mg/day), all cases finally turned real-time reverse transcription polymerase chain reaction (RT-PCR) negative.
Conclusion: Our cases suggested that proxalutamide might be an effective remedial treatment option for patients experiencing a COVID-19 rebound after Paxlovid treatment.

Keywords: COVID-19; COVID-19 rebound; Paxlovid; case report; proxalutamide.